- Recommendation ID
- DG16/4
- Question
- NICE recommended further research to explore the impact of having experiences of patients having continuous infusion 5-FU and take into account the impact on quality of life. The potential consequences of introducing pharmacokinetic dose adjustment should also be explored.
- Any explanatory notes
(if applicable) - None.
Source guidance details
- Comes from guidance
- Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment
- Number
- DG16
- Date issued
- December 2014
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 07/01/2015 |